A Phase 1 Open-Label, Safety, Pharmacokinetic and Preliminary Efficacy Study of STRO-001, an Anti-CD74 Antibody Drug Conjugate, in Patients With Advanced B-Cell Malignancies
Phase of Trial: Phase I
Latest Information Update: 09 Apr 2018
At a glance
- Drugs STRO 001 (Primary)
- Indications Multiple myeloma; Non-Hodgkin's lymphoma
- Focus Adverse reactions; First in man; Therapeutic Use
- Sponsors Sutro Biopharma
- 22 Feb 2018 Status changed from not yet recruiting to recruiting.
- 12 Dec 2017 According to a Sutro Biopharma media release, company plans to submit IND application by the end of 2017 and initiate the trial in Q1 2018.
- 19 Jul 2017 New trial record